C
Christoph Bode
Researcher at University of Freiburg
Publications - 710
Citations - 22447
Christoph Bode is an academic researcher from University of Freiburg. The author has contributed to research in topics: Myocardial infarction & Medicine. The author has an hindex of 63, co-authored 680 publications receiving 19027 citations. Previous affiliations of Christoph Bode include University of North Carolina at Chapel Hill & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega,Eugene Braunwald,Stephen D. Wiviott,Jean-Pierre Bassand,Deepak L. Bhatt,Christoph Bode,Paul Burton,Marc Cohen,Nancy Cook-Bruns,Shinya Goto,Sabina A. Murphy,Alexei N. Plotnikov,David J. Schneider,Xiang Sun,C. Michael Gibson +14 more
TL;DR: In patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in a double-blind, placebo-controlled trial.
Journal ArticleDOI
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
C. Michael Gibson,Roxana Mehran,Christoph Bode,Jonathan L. Halperin,Freek W Verheugt,Peter Wildgoose,Mary Birmingham,Juliana Ianus,Paul W. Burton,Martin van Eickels,Serge Korjian,Yazan Daaboul,Gregory Y.H. Lip,Marc Cohen,Steen Elkjær Husted,Eric D. Peterson,Keith A.A. Fox +16 more
TL;DR: In participants with atrial fibrillation undergoing PCI with placement of stents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose thrombolysis in Myocardial Infarction plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding.
Journal ArticleDOI
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci,Zhen Huang,Claes Held,David J. Moliterno,Paul W. Armstrong,Frans Van de Werf,Harvey D. White,Philip E. Aylward,Lars Wallentin,Edmond Chen,Yuliya Lokhnygina,Jinglan Pei,Sergio Leonardi,Tyrus Rorick,Ann M. Kilian,Lisa K. Jennings,Giuseppe Ambrosio,Christoph Bode,Angel Cequier,Jan H. Cornel,Rafael Diaz,Aycan Fahri Erkan,Kurt Huber,Michael P. Hudson,Lixin Jiang,J. Wouter Jukema,Basil S. Lewis,A. Michael Lincoff,Gilles Montalescot,Jose C. Nicolau,Hisao Ogawa,M Pfisterer,Juan Carlos Prieto,Witold Rużyłło,Peter Sinnaeve,Robert F. Storey,Marco Valgimigli,David J. Whellan,Petr Widimsky,John Strony,Robert A. Harrington,Kenneth W. Mahaffey +41 more
TL;DR: In patients with acute coronary syndromes, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite end point but significantly increased the risk of major bleeding, including intracranial hemorrhage.
Journal ArticleDOI
Chronic variable stress activates hematopoietic stem cells
Timo Heidt,Hendrik B. Sager,Gabriel Courties,Partha Dutta,Yoshiko Iwamoto,Alex Zaltsman,Constantin von zur Mühlen,Christoph Bode,Gregory L. Fricchione,John W. Denninger,Charles P. Lin,Claudio Vinegoni,Peter Libby,Filip K. Swirski,Ralph Weissleder,Matthias Nahrendorf +15 more
TL;DR: It is shown that stress increases proliferation of these most primitive hematopoietic progenitors, giving rise to higher levels of disease-promoting inflammatory leukocytes and monocytosis and neutrophilia in humans.
Journal ArticleDOI
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
Robert P. Giugliano,Jennifer A. White,Christoph Bode,Paul W. Armstrong,Gilles Montalescot,Basil S. Lewis,Arnoud W J van 't Hof,Lisa G. Berdan,Kerry L. Lee,John Strony,Steven Hildemann,Enrico P. Veltri,Frans Van de Werf,Eugene Braunwald,Robert A. Harrington,Robert M. Califf,L. Kristin Newby +16 more
TL;DR: In patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of EPTifib atide after angiographic, and the early use ofeptifIBatide was associated with an increased risk of non-life-threatening bleeding and need for transfusion.